Alzheimer's disease (AD) is a common neurodegenerative brain disorder that causes
cellular response alterations, such as impaired cholinergic mechanism, amyloid‐beta (Aβ) …

Neuritic plaques in the brains are one of the pathological hallmarks of Alzheimer's disease
(AD). Amyloid β-protein (Aβ), the central component of neuritic plaques, is derived from β …

Neuritic plaques in the brain are a major neuropathological hallmark of Alzheimer's disease.
They are formed by the deposition and aggregation of extracellular amyloid-β protein (Aβ) …

Diabetes and Alzheimer's disease are two highly prevalent diseases among the aging
population and have become major public health concerns in the 21st century, with a …

Alzheimer disease (AD) results, in part, from the excess accumulation of the amyloid-β (Aβ)
peptide as neuritic plaques in the brain. The short Aβ peptide is derived from the large …

A key event in the pathogenesis of Alzheimer's disease (AD) is the accumulation of amyloid-
β (Aβ) species in the brain, derived from the sequential cleavage of the amyloid precursor …

Mitogen-activated protein kinase (MAPK) phosphatase 1 (MKP-1) is an essential negative
regulator of MAPKs by dephosphorylating MAPKs at both tyrosine and threonine residues …

Beta-site APP cleaving enzyme 1 (BACE1) is the rate limiting enzyme for accumulation of
amyloid β (Aβ)-peptide in the brain in Alzheimer's disease (AD). Oxidative stress (OS) that …

The concept of chelation therapy as a valuable therapeutic approach in neurological
disorders led us to develop multi-target, non-toxic, lipophilic, brain-permeable compounds …

Observations of elevated basal cortisol levels in Alzheimer's disease (AD) patients prompted
the hypothesis that stress and glucocorticoids (GC) may contribute to the development …